Clarithromycin/Amoxicillin/Vonoprazan Fumarate

克拉霉素/阿莫西林/富马酸伏诺拉生

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameClarithromycin/Amoxicillin/Vonoprazan Fumarate
Drug Alias NameVonosapVoquezna Triple Pak
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibioticsSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsPotassium-transporting ATPase inhibitorsBacterial penicillin-binding protein inhibitors
Targets50S ribosomal subunitPotassium-transporting ATPaseBacterial penicillin-binding protein
Therapy Area/IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6] 
Global Approved IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2016/02/25
Country/TerritoryUnited StatesJapan
CombinationsYes ClarithromycinAmoxicillinVonoprazan Fumarate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPhathom Pharmaceuticals IncTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeA02BD14
Related LinksKEGG